ADVA
14.7.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it’s partnering with OTN Systems to address key connectivity challenges for industrial applications. The companies are teaming up to offer joint end-to-end networking solutions built with best-in-class technology and specifically designed for the industry sector. Now customers in transportation, oil and gas, mining and electrical power utilities can smoothly transition from their legacy SONET/SDH infrastructure and realize the benefits of packet transport. Featuring OTN Systems’ XTran MPLS-TP layer combined with ADVA FSP 3000 OLS technology, the tailor-made solutions are ruggedized for the harshest environments. They also provide stringent synchronization and comprehensive in-service monitoring, ensuring the levels of availability needed for the most advanced industrial demands.
”By joining forces with ADVA, we’re giving customers the full benefits of our combined innovation and expertise. Our companies share a goal of helping all industries on their digital transformation journeys. By delivering integrated end-to-end networks that precisely meet sector-specific requirements, we’re empowering our customers to take that next step,” said Jurgen Michielsen, CTO, OTN Systems. “From transportation to electric utilities, today’s industrial networks operators are looking for a seamless way to evolve their old SONET/SDH infrastructure to high-capacity packet-based network technology. The joint solution allows customers to make the jump to the next generation of telecom architecture simple, risk-free and extremely cost-effective.”
To keep pace with the demands of new applications, industrial networks must deliver greater bandwidth and improved quality of service. They need technology that supports an easy transition from increasingly obsolete SONET/SDH networks to packet-optical transport architectures. That’s precisely what ADVA and OTN Systems’ joint solutions provide. They enable operational infrastructure to cater for ever-increasing amounts of data traffic and support industrial automation. The combined solutions include the ADVA FSP 3000 OLS, which efficiently transports wavelengths over long distances using multiplexing, amplification, dispersion compensation, power leveling and wavelength routing. This is combined with OTN Systems’ XTran multi-service MPLS-TP platform designed for industrial applications. Growing security threats are also addressed with the protection of ADVA FSP 3000 ConnectGuard™ Optical encryption as well as strict synchronization needs with ADVA’s Oscilloquartz portfolio.
“We’re teaming up with OTN Systems to deliver industrial connectivity with a unique set of benefits. Together we can provide the most reliable and secure end-to-end networking solutions on the market – solutions that are fully optimized for next-generation industrial applications and specifically designed to withstand the most extreme environments,” commented Christoph Glingener, CTO, ADVA. “Our FSP 3000 enables industrial networks to minimize both cost per bit and operational efforts. Our joint customers can also further enhance performance and reduce operating costs with our ADVA ALM fiber monitoring solution. This gives industrial network operators full control with real-time insight into the fiber plant. What’s more, our Oscilloquartz technology range ensures the precise synchronization needed for ultra-low latency use cases.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About OTN Systems
OTN systems is a leading supplier of mission-critical telecommunication solutions to industrial customers for more than 30 years. The company has developed a unique next generation platform tailored for industrial applications. XTran is a flexible, state-of-the-art product allowing customers to go full packet. Its underlying MPLS-TP technology avoids the complexity of generic telecom solutions developed for service providers. XTran secures reliable operations in a harsh environments, while its management system (TXCare) supports an intuitive and simple handling. Since its market introduction back in 2014, more than 100 customers worldwide have deployed XTran. For more information on our product and services offering, please visit us at www.otnsystems.com
, allowing you to fully appreciate how “we make MPLS for Operational Telecom easy.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005053/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom